Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

21 Dec 2015 18:22

RNS Number : 8050J
GW Pharmaceuticals PLC
21 December 2015
 



GW Pharmaceuticals PLC Director/PDMR Shareholding

21 December 2015

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals" or the "Company")

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

 

Cambridge, UK, 21 December 2015: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has been notified of the following series of transactions in the shares of GW Pharmaceuticals plc.

 

On 18 December 2015 the Company was notified that on 17 December 2015 Mr Cabot Brown, a non-executive Director of the Company, purchased 600 American Depository Shares, or ADS (equivalent to 7,200 ordinary 0.1 pence shares) of GW Pharmaceuticals plc, at a price of $68.864 per ADS (equivalent to 384 pence per share).

 

Following this notification Mr Brown's interest in the shares of GW Pharmaceuticals plc is 7,200 ordinary 0.1 pence shares (equivalent to 600 ADSs), representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Mr. Chris Tovey, a Director and Chief Operating Officer of the Company, exercised options to acquire 24,000 ordinary 0.1 pence shares (equivalent to 2,000 ADSs) of GW Pharmaceuticals plc. These options had an exercise price of 0.1 pence per share. The Company has been notified that on 18 December 2015 these shares, representing less than 0.1% of shares in issue, were converted to 2,000 ADSs and immediately sold at an average price of $67.6275 per ADS (equivalent to 378 pence per share).

 

Following these transactions, Mr. Tovey's beneficial interested in the Company's ordinary 0.1 pence shares is 2,500 shares, representing less than 0.1% of the Company's current issued share capital.

 

On 18 December 2015 Dr. Geoffrey Guy, a Director and Chairman of the Company, exercised options to acquire 1,369,848 ordinary 0.1 pence shares (equivalent to 114,154 ADSs) of GW Pharmaceuticals plc. These options had a weighted average exercise price of 41 pence per ordinary 0.1 pence share. The Company has been notified that (1) on 18 December 2015, 1,065,936 of these shares were converted to 88,828 ADSs and immediately sold at an average price of $67.50 per ADS (equivalent to 377 pence per share) and (2) earlier today a further 10,309 ADSs (equivalent to 123,708 ordinary 0.1 pence shares) were sold at an average price of $67.32 per ADS (equivalent to 376 pence per share). Exercise of these options results in an immediate UK income tax liability for Dr. Guy necessitating the immediate sale of a significant number of the resulting shares. In addition, we have been notified that earlier today 6,000 ordinary 0.1 pence shares held by Dr Guy's personal pension scheme were sold at an average price of 366 pence per share.

 

Following these transactions, Dr. Guy's notifiable interest in the ordinary 0.1 pence shares of the Company has increased by 174,204 shares to 14,297,852 shares, representing 5.4% of the Company's current issued share capital.

 

The total number of shares outstanding in the Company is 262,574,021 ordinary 0.1 pence shares.

 

For further information, please contact:

 

GW Pharmaceuticals plc

Adam George, Company Secretary

+44 (0)1980 557 000

Peel Hunt LLP (UK NOMAD)

James Steel

+44 20 7418 8900

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSLLFFTFLLLFIE
Date   Source Headline
10th May 20134:24 pmRNSHolding(s) in Company
9th May 20133:40 pmRNSTotal Voting Rights
8th May 20138:00 amRNSClosing of Initial Public Offering on Nasdaq
7th May 20137:00 amRNSSativex Commercialization Approval in Italy
1st May 20135:47 pmRNSPricing of U.S. Initial Public Offering
22nd Apr 20137:00 amRNSUS Patent Allowance for SATIVEX Formulation Spray
18th Apr 20132:23 pmRNSAmendment to Registration Statement for NASDAQ
12th Apr 201310:31 amRNSResults of General Meeting
10th Apr 20137:00 amRNSSativex moved to Schedule 4 of UK Drugs Act
3rd Apr 20137:00 amRNSNew US Patent Allowance for Delivery of SATIVEX
22nd Mar 20132:35 pmRNSPosting of Shareholder Circular
19th Mar 20132:46 pmRNSAppoints Stephen Schultz VP of Investor Relations
19th Mar 20131:10 pmRNSUpdate on Sativex in Germany
19th Mar 20131:01 pmRNSFiling for listing on NASDAQ
19th Feb 20133:16 pmRNSDirectorate Change
19th Feb 20139:30 amRNSBlocklisting Interim Review
4th Dec 201210:04 amRNSDirector/PDMR Shareholding
30th Nov 20122:54 pmRNSDirector/PDMR Shareholding
30th Nov 20122:50 pmRNSDirector/PDMR Shareholding
28th Nov 20127:00 amRNSPreliminary Results
28th Nov 20127:00 amRNSPhIIa Study Identifies New Anti-Diabetic Treatment
22nd Nov 201211:31 amRNSNotice of Results
12th Nov 20127:00 amRNSGW to Present at Lazard Healthcare Conference
12th Oct 20127:00 amRNSPositive German Sativex Data Presented at ECTRIMS
1st Oct 20127:00 amRNSAppointment of Chief Operating Officer
13th Sep 20127:00 amRNSPublication of New Epilepsy Data
20th Aug 201212:14 pmRNSDirector/PDMR Shareholding
17th Aug 20124:04 pmRNSBlocklisting Interim Review
22nd Jun 20127:00 amRNSGerman GBA establishes positive benefit of Sativex
13th Jun 201210:19 amRNSDirector/PDMR Shareholding
6th Jun 20124:03 pmRNSDirector/PDMR Shareholding
23rd May 20123:56 pmRNSDirector/PDMR Shareholding
22nd May 20127:00 amRNSThird Cancer Pain Trial Commences
22nd May 20127:00 amRNSInterim Results
8th May 20127:00 amRNSSuccessful completion of MRP for Sativex
26th Apr 201211:00 amRNSNotice of Results
23rd Apr 20127:00 amRNSSativex phase IIb pain trial results publication
16th Apr 20127:00 amRNSAlmirall Milestone
5th Apr 20127:00 amRNSBoard Changes
2nd Apr 20122:31 pmRNSDirector/PDMR Shareholding
30th Mar 20121:57 pmRNSDirector/PDMR Shareholding
15th Mar 20127:00 amRNSGW and Almirall Strengthen Strategic Collaboration
8th Mar 20127:00 amRNSAppointment of Professor Vincenzo Di Marzo
17th Feb 20127:00 amRNSBlocklisting Interim Review
7th Feb 20127:00 amRNSSATIVEX® Regulatory Approval Received in Austria
25th Jan 20121:46 pmRNSResult of AGM
11th Jan 201211:43 amRNSHolding(s) in Company
11th Jan 201211:42 amRNSHolding(s) in Company
28th Dec 201110:39 amRNSDirector/PDMR Shareholding
22nd Dec 20117:00 amRNSSativex Approval in Sweden

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.